Skip to main content
Enter your The Contraceptive Pipeline Database username.
Enter the password that accompanies your username.
Vicriviroc + MK2048 + Progestin Vaginal Ring
A vaginal ring whose mechanism of action is CCR5 inhibitor, integrase inhibitor and a progestin for protection against HIV and pregnancy.
May 11, 2015
Active Pharmaceutical Ingredient (API):
Potential Multi-Purpose Technology (MPT):
2-ARV IVR prototype first in human study planned in early 2015. 2-ARV+progestin IVR prototype in preclinical development.
Merck announced that it would discontinue development of its investigational CCR5 antagonist vicriviroc for the treatment of HIV infection in both treatment-naive and treatment-experienced patients, due to unimpressive results in clinical trials.
Nuvaring technology licensed, manufacturing infrastructure. Nuvaring postmarket acceptability studies completed.
Vicriviroc is also known as MK4176.
Download Product Report